SCHEMBL451654

SCHEMBL451654

Nc1c(O)cc(C(=O)O)cc1-c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.50
BAD Q92934 1/20 0.50
MAP4K4 O95819 1/20 0.50
IKBKB O14920 2/20 0.44
CHUK O15111 2/20 0.44
KDM4E B2RXH2 6/20 0.42
LMNA P02545 4/20 0.42
HSD17B10 Q99714 4/20 0.42
GPR35 Q9HC97 1/20 0.42
MAPT P10636 5/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
CA12 O43570 3/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL452184 0.82 PTGS1 (0.49) IKBKBCHUKKDM4ELMNAMAPT
SCHEMBL4428101 0.80 BCL2L1 (0.62) BCL2L1BADMAP4K4KDM4ELMNA
SCHEMBL19404312 0.78 BCL2L1 (0.60) BCL2L1BADMAP4K4KDM4ELMNA
SCHEMBL3174622 0.74 CA12 (0.64) KDM4ELMNAHSD17B10MAPTCA1
SCHEMBL28476726 0.71 BCL2L1 (0.60) BCL2L1BADMAP4K4KDM4ELMNA
SCHEMBL15157461 0.71 BCL2L1 (0.72) BCL2L1BADMAP4K4KDM4ELMNA
SCHEMBL3475708 0.71 BCL2L1 (0.72) BCL2L1BADMAP4K4KDM4ELMNA
SCHEMBL27640008 0.71 BCL2L1 (0.50) BCL2L1BADMAP4K4KDM4ELMNA
SCHEMBL2745136 0.70 BCL2L1 (0.58) BCL2L1BADMAP4K4MEN1KMT2A
SCHEMBL29625290 0.70 MAP4K4 (0.54) BCL2L1BADMAP4K4TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed
EP-2410857-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
WO-2010111058-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 BCL2L1 3209/4885BAD 821/4885MAP4K4 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.